MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Actinium Pharmaceuticals Inc

Cerrado

1.49 -3.87

Resumen

Variación precio

24h

Actual

Mínimo

1.48

Máximo

1.55

Métricas clave

By Trading Economics

Ingresos

-9.3M

-16M

Empleados

31

EBITDA

-9.3M

-17M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+287.1% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-3.4M

45M

Apertura anterior

5.36

Cierre anterior

1.49

Actinium Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Charlas de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Ganancias

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Ganancias

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Ganancias

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Ganancias

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Ganancias

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Ganancias

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Ganancias

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Ganancias

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Ganancias

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Ganancias

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Ganancias

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Ganancias

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Ganancias

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Charlas de Mercado

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparación entre iguales

Cambio de precio

Actinium Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

287.1% repunte

Estimación a 12 meses

Media 6 USD  287.1%

Máximo 9 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Actinium Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.